PRESS RELEASES

Date Title and Summary View
Dec 4, 2012
Summary ToggleZafgen Secures $21 Million in Series D Financing

Alta Partners Joins Investor Syndicate to Lead New Funding<br /><br />Proceeds to Advance Development of Obesity Therapeutic Beloranib

Summary ToggleZafgen Secures $21 Million in Series D Financing
Nov 6, 2012
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
Sep 22, 2012
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society

Findings Show Treatment with Beloranib Resulted in Rapid Weight Loss, Corresponding Reductions in Multiple Cardiovascular Risk Factors in Severely Obese Subjects

Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
Jun 10, 2012
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®

Results Show Treatment with Beloranib Resulted in Weight Loss and Corresponding Reductions in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects

Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Oct 13, 2011
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
Sep 28, 2011
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
Sep 21, 2011
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
Jul 7, 2011
Summary ToggleZafgen Secures $33 Million Series C Financing

Proceeds to Advance Zafgen&#8217;s Lead Compound for Severe Obesity into Phase 2 Clinical Studies

Summary ToggleZafgen Secures $33 Million Series C Financing
Jun 24, 2011
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting

Results Show MetAP2 Inhibitor Treatment Improves Cardiovascular Risk Markers in Severely Obese Subjects

Company Also Announces Initiation of Dose Escalation Trial in Obese Women

Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Apr 8, 2011
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference